Literature DB >> 26210374

MRI and intraoperative pathology to predict nipple-areola complex (NAC) involvement in patients undergoing NAC-sparing mastectomy.

Riccardo Ponzone1, Furio Maggiorotto2, Silvia Carabalona3, Alessandro Rivolin2, Alberto Pisacane4, Franziska Kubatzki2, Stefania Renditore2, Salvatore Carlucci2, Paola Sgandurra2, Francesco Marocco2, Alessandra Magistris2, Daniele Regge3, Laura Martincich3.   

Abstract

BACKGROUND: Nipple-areola sparing mastectomy (NSM) with immediate implant reconstruction is an option for patients with non-locally advanced breast cancer. The prediction of occult tumour involvement of the nipple-areola complex (NAC) may help select candidates to NSM. PATIENTS AND METHODS: We prospectively recorded clinical and pathological data, magnetic resonance imaging (MRI) results and intraoperative pathological assessments of the subareolar (SD) and proximal nipple ducts (ND) of 112 consecutive breast cancer patients scheduled for NSM. All parameters were correlated with final pathological NAC assessment by univariate and multivariate analysis.
RESULTS: Thirty-one patients (27.7%) had tumour involvement of the NAC. At univariate analysis, age (p=0.001), post-menopausal status (0.003), tumour central location (p=0.03), tumour-NAC distance measured by MRI (p=0.000) and intraoperative pathologic assessment (SD+ND) (p=0.000) were significantly correlated with NAC involvement. At multivariate analysis, only MRI tumour-NAC distance (p=0.008) and menopausal status (p=0.039) among all preoperative variables retained statistical significance. The sensitivity and specificity of MRI tumour-NAC distance were 32.2% and 88.6% and those of intraoperative pathologic assessment were 46.7% and 100%, respectively. Sensitivity, specificity and accuracy of the double assessment (MRI plus intraoperative pathology) were 50.0%, 96.2% and 84.1%, respectively.
CONCLUSION: Intraoperative pathologic assessment and tumour-NAC distance measured by MRI are the most important predictors of occult NAC involvement in breast cancer patients. A negative pathological assessment and a tumour-NAC distance ⩾ 5 mm allow optimal discrimination between NAC positive and NAC negative cases and may serve as a guide for the optimal planning of oncological and reconstructive surgery.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Intraoperative pathology; Magnetic resonance imaging; Mastectomy, nipple–areola sparing

Mesh:

Year:  2015        PMID: 26210374     DOI: 10.1016/j.ejca.2015.07.001

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  14 in total

Review 1.  Implant Reconstruction in Nipple Sparing Mastectomy.

Authors:  Carrie K Chu; Matthew J Davis; Amjed Abu-Ghname; Sebastian J Winocour; Albert Losken; Grant W Carlson
Journal:  Semin Plast Surg       Date:  2019-10-17       Impact factor: 2.314

2.  Preservation of the nipple-areola complex in skin-sparing mastectomy for early breast cancer.

Authors:  Ryo Miyake; Satoki Kinoshita; Naoko Shimada; Ken Uchida; Hiroshi Takeyama; Toshiaki Morikawa
Journal:  Surg Today       Date:  2018-02-21       Impact factor: 2.549

3.  Preoperative Ultrasound-guided Sub-areolar Biopsy in Predicting Occult Nipple Involvement in Breast Cancer Patients: Proposal for a Methodological Approach.

Authors:  Vittorio Altomare; Paolo Orsaria; Antonella Grasso; Lorenza Caggiati; Edy Ippolito; Francesco Pantano; Matteo Sammarra; Carlo Altomare; Giuseppe Perrone; Gabriella Gullotta; Rita Carino
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

4.  Oncological Safety and Technical Feasibility of Nipple-Sparing Mastectomy for Breast Cancer: The Hong Kong Experience.

Authors:  Yolanda Ho-Yan Chan; Wai-Ming Yau; Polly Suk-Yee Cheung
Journal:  World J Surg       Date:  2018-05       Impact factor: 3.352

5.  Tumor-Nipple Distance of ≥ 1 cm Predicts Negative Nipple Pathology After Neoadjuvant Chemotherapy.

Authors:  Tracy-Ann Moo; Carolina Rossi Saccarelli; Elizabeth J Sutton; Varadan Sevilimedu; Kate R Pawloski; Timothy M D'Alfonso; Mary C Hughes; Jill S Gluskin; Almir Bitencourt; Elizabeth A Morris; Audree Tadros; Monica Morrow; Mary L Gemignani; Virgilio Sacchini
Journal:  Ann Surg Oncol       Date:  2021-04-17       Impact factor: 4.339

6.  The impact of malignant nipple discharge cytology (NDc) in surgical management of breast cancer patients.

Authors:  Isabella Castellano; Jasna Metovic; Davide Balmativola; Laura Annaratone; Nelson Rangel; Elena Vissio; Riccardo Arisio; Luigia Macrì; Carla Pecchioni; Ivana Sarotto; Francesca Montarolo; Francesca Muscarà; Caterina Marchiò; Paola Cassoni; Janina Kulka; Anna Sapino
Journal:  PLoS One       Date:  2017-08-14       Impact factor: 3.240

7.  Role of breast magnetic resonance imaging in predicting malignant invasion of the nipple-areolar complex: Potential predictors and reliability between inter-observers.

Authors:  Chiung-Ying Liao; Yu-Ting Wu; Wen-Pei Wu; Chih-Jung Chen; Hwa-Koon Wu; Ying-Jen Lin; Shou-Tung Chen; Dar-Ren Chen; Chi-Wei Lee; Shu-Ling Chen; Shou-Jen Kuo; Hung-Wen Lai
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

8.  Oncologic Safety of Immediate Breast Reconstruction for Invasive Breast Cancer Patients: A Matched Case Control Study.

Authors:  Shin-Hoo Park; Wonshik Han; Tae-Kyung Yoo; Han-Byoel Lee; Ung Sik Jin; Hak Chang; Kyung Won Minn; Dong-Young Noh
Journal:  J Breast Cancer       Date:  2016-03-25       Impact factor: 3.588

9.  Mastectomy Flap Thickness and Complications in Nipple-Sparing Mastectomy: Objective Evaluation using Magnetic Resonance Imaging.

Authors:  Jordan D Frey; Ara A Salibian; Mihye Choi; Nolan S Karp
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-08-08

10.  Clinical value of delayed 18F-FDG PET/CT for predicting nipple-areolar complex involvement in breast cancer: A comparison with clinical symptoms and breast MRI.

Authors:  Jang Yoo; Bom Sahn Kim; Jin Chung; Hai-Jeon Yoon
Journal:  PLoS One       Date:  2018-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.